Pliant Therapeutics to Participate in Upcoming Investor Conferences
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis therapies, will participate in two investor conferences in September 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis therapies, will participate in two investor conferences in September 2022. The conferences are Citi's 17th Annual BioPharma Conference from September 6-7, and H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, where a pre-recorded fireside chat will be accessible on September 12 at 7:00 a.m. ET. Pliant's lead product candidate, PLN-74809, is under Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received various designations from the FDA and EMA.
Details
News Market Reaction – PLRX
The recorded move for PLRX in the trading session of this news was -3.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant’s senior management will participate in the following September investor conferences:
- Citi's 17th Annual BioPharma Conference on September 6 – 7, 2022 at the Four Seasons Hotel, Boston, Massachusetts
- H.C. Wainwright 24th Annual Global Investment Conference virtually on September 12 – 14, 2022. Dr Coulie’s pre-recorded fireside chat will be available on Monday, September 12, 2022, at 7:00 a.m. ET
Interested parties can access the H.C. Wainwright fireside chat from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time it is made available.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.